





PTO/SB/05 (11-00)

📆 Please type a sign (+) inside this box \Rightarrow 🖽

Approved for use through 10/31/2002 OMB 0651-0032

= →	k Reduction Act of 1995, no person	s are required to resp	Par ond to a coll	tent and Trademark	Office: U.S. DEF	PARTMENT OF COMME is a valid OMB control num	RCF		
	UTILITY			ry Docket No.	····	PA106	2		
РАТ	TENT APPLICAT	ION	First In	iventor		Rosen et al.	٦.		
TRANSMITTAL				Title Nucleic Acids, Proteins and Antibo					
(Only for new	nonprovisional applications under 37	CFR ' 1.53(b))	Express	s Mail Label No.			25		
_	PPLICATION ELEMEN upter 600 concerning utility patent app	-	ADDR	RESS TO:	Assistant Commis Box Patent Appli Washington, DC		JC47		
1. Eee Trans (Submit an o	smittal Form (e.g., PTO/SB/17) priginal, and a duplicate for fee proces	ssing)	 CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) Computer Readable Form (CRF) Specification Sequence Listing on: CD-ROM or CD-R (2 copies); or paper [Total Pages:] Statements verifying identity of above copies 						
2. Applicant See 37 Cl	t claims small entity status. FR 1.27.								
- Descriptive - Cross Refe - Statement I	ation [Total Pages rrangement set forth below) e title of the Invention rence to Related Applications Regarding Fed sponsored R & D to sequence listing, a table,	: <u>635</u>]							
or a compu	tter program listing appendix d of the Invention	r program listing appendix			ACCOMPANYING APPLICATION PARTS				
- Brief Sum -Brief-Desci - Detailed D - Claim(s) - Abstract o	nary of the Invention ription of the Drawings (if filed) escription f the Disclosure		9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of Attorney 11. English Translation Document (if applicable) 12. Information Disclosure Statement/ Form PTO/SB/08						
	s) (35 U.S.C. 113) [Total Shee Declaration [Total Pages		13.	Copies of Citations					
b. Copy for co i. DELE Signed s the prior	y executed (original) from a prior application (37 (intinuation/divisional with Box 17 TION OF INVENTOR(S) statement attached deleting inventer application, see 37 CFR ' ' 1.63 in Data Sheet. See 37 CFR 1.	or(s) named in (d)(2) and 1.33(b).	 13. ☐ Preliminary Amendment 14. ☐ Return Receipt Postcard (MPEP 503) (should be specifically iternized) 15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. ☐ Other: Transmittal and Submission Under 37 C.F.R. §§ 1.824 and 1.52(e) 						
	UING APPLICATION, check	appropriate box, an	d supply the	requisite informa	tion below and in	a preliminary amendme	nt,		
Continuation Prior application For CONTINUATION OR D		Continuation-in-Particle of the prior application, rated by reference. The in	_ G	Froup/Art Unit:	pplied under Box 5b, is a a portion has been inc	considered a part of the disclosu	re of the mitted		
18. CORRESPON	NDENCE ADDRESS								
NAME									
(DDDE65						.			
ADDRESS CITY		STATE			ZIP CO	DF			
COUNTRY		TELEPHONE			FAX				
NAME (Print/Type)	Michele M. Wales			Registration	n No. (Attorney/Age	ent) 43,975			
SIGNATURE	Marila	Wall	/		Date 8	1010			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231



of information unless it displays a valid OMB control number.

rk Reduction Act of 1995. Complete if Known **FEE TRANSMITTAL** for FY 2001 Patent fees are subject to annual revision. Application Number Unassigned Filing Date Herewith First Named Inventor Rosen et al. Examiner Name Unassigned Group Art Unit Unassigned \$1,132.00 Attorney Docket Number Total amount of payment PA106 METHOD OF PAYMENT (CHECK ONE) FEE CALCULATION (CONTINUED) 1. The Commissioner is hereby authorized to charge indicated ADDITIONAL FEES fees and credit any overpayment to: Large Entity Small Entity Deposit Account 08-3425 Fee Fee Fee Fee Fee Paid Number Code (\$) Description Code **(S)** Deposit Account Human Genome Sciences, Inc. Surcharge - late filing of Oath or Declaration 105 130 205 65 Name 127 50 227 25 Surcharge - late provisional filing fee or cover harge Any Additional Fee Required 139 130 139 130 Non-English specification Inder 37 CFR §§ 1.16 and 1.17 147 2.520 147 2,520 For filing a request for ex parte reexamination 112 920 112 920 Requesting publication of SIR prior to Examiner Applicant claims small entity status 113 1.840 113 1.840 Requesting publication of SIR after Examiner See 37 CFR 1.27 110 215 55 Extension for reply-within first month 116 390 216 195 Extension for reply within second month 2 Payment Enclosed: 117 890 217 445 Extension for reply within third month ☐ Check ☐ Credit Card ☐ Money Order ☑ Other 118 1,390 218 695 Extension for reply within fourth month Charge any deficiencies or credit any overpayments in the fees or fee 128 1,890 228 945 Extension for reply within fifth month calculations of Parts 1, 2 and 3 below to Deposit Account No. 08-3425 310 219 155 Notice of Appeal FEE CALCULATION 120 310 220 155 Filing a brief in support of an appeal T. BASIC FILING FEE 121 270 221 135 Request for oral hearing :: Large Entity Small Entity Fee 138 1,510 138 1,510 Petition to institute a public use proceeding Fee Fee Fee Description Paid ≃Ĉode (\$) Code **(S)** Utility filing fee \$710.00 710 201 355 140 110 240 55 Petition to revive -unavoidable <u>...≟</u>106 320 206 160 Design filing fee 141 1,240 241 620 Petition to revive - unintentional 107 490 207 245 Plant filing fee 142 1,240 242 620 Utility issue fee (or reissue) 108 710 208 355 Reissue filing fee 440 143 243 Design issue fee .08 114 Provisional filing fee 150 214 75 144 600 244 300 Plant issue fee 130 122 130 Petitions to the Commissioner <u>.</u> \$710.00 Subtotal (1) 123 50 123 50 Petitions related to provisional applications 180 180 126 126 Submission of Information Disclosure Statement 2. EXTRA CLAIM FEES 581 40 481 40 Recording each patent assignment per property (times number of properties) Fee from Fee 146 710 246 355 Filing a submission after final rejection Extra below Paid (37 CFR 1.129(a)) 149 710 249 355 For each additional invention to be examined (37

											CFR 1.125(0))
Indep.cl	aims	4	- 3**	1	\$80.00	\$ 80.00	179	710	279	355	Request for Continued Examination (RCE)
Multiple	:	1		1	\$270.00	\$270.00	169	190	169	900	Request for expedited examination of a design
Depende	ent					L					application
							Other fo	ee (specify)):		
Large	Entity	Smalt	Entity	Fee			Other fee (specify):				
Fee	Fee	Fee	Fee	Description							•
Code	(\$)	Code	(\$)								
				-			Reduce	ed by Basic	c Filing F	ee Paid	
103	18	203	9	Claims in excess of 20							
102	80	202	40	Independent claims in excess of 3			l				
104	270	204	135	Mutliple dependent claim			Ì				
108	80	209	40	**Reissue independent claims		ļ.					
				over ori	ginal patent						
110	18	210	9		ue claims in e						Subtotal (3)
				and ove	r original pate	nt					

\$ 72.00

\$422.00

Submitted By Michele M. Wales Name (Print/Type)

Total claims

Subtotal (2)

Signature:

Complete (if applicable) Registration No.: 43,975 Telephone (301) 610-5772

\$0.00

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rosen et al.

Attorney Docket No.: PA106

Application Serial No.: Unassigned

Art Unit: Unassigned

Filed: Herewith

Examiner: Unassigned

Title: Nucleic Acids, Proteins and Antibodies

TRANSMITTAL AND SUBMISSION UNDER 37 C.F.R. §§ 1.824 and 1.52(e)

Commissioner For Patents Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.821(e) and 1.824, Applicants submit herewith a Sequence Listing satisfying the computer-readable format requirements on a compact disc (CD-R) labeled "CRF." Applicants submit concurrently herewith a Statement Under 37 C.F.R. § 1.821.

Additionally, in accordance with 37 C.F.R. §§ 1.52(e), 1.821, and 1.823, Applicants submit herewith a Sequence Listing as an electronic document on two identical compact discs (CD-Rs). Applicants certify under 37 C.F.R. §1.52(e)(4) that these two compact discs, labeled "Copy 1" and "Copy 2," are identical. These compact discs, formatted for an IBM-PC machine and compatible with the MS-Windows operating system, contain the following file:

> 1. Name of File: PA106SEQLIST.txt

2. Size: 3,120,732 bytes

3. Date of Creation: August 8, 2001

Respectfully submitted,

Dated: QUGLO 200

Attorney for Applicants

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850 Telephone: (301) 610-5772

Fax: (301) 309-8439

MMW/CCB/ba

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rosen et al.

Attorney Docket No.: PA106

Application Serial No.: Unassigned

Art Unit: Unassigned

Filed: Herewith

Examiner: Unassigned

Title: Nucleic Acids, Proteins and Antibodies

STATEMENT UNDER 37 C.F.R. § 1.821(f)

Commissioner For Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.821(f), Applicants hereby certify that the Sequence Listing information-recorded in computer-readable-form and submitted herewith is identical to the written (on compact disc) Sequence Listing submitted herewith.

Respectfully submitted,

Dated: (200)

Michele M. Wales (Reg. No. 43,975)

Attorney for Applicants

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850

Telephone: (301) 610-5772

MMW/CCB/ba